News & Updates
Showing Multidisciplinary articles
Showing

DESTINY-Breast03 reports longest OS in previously treated HER2-positive mBC
Long-term follow-up of the DESTINY-Breast03 trial has reported a median overall survival (OS) of 52.6 months with trastuzumab deruxtecan (T-DXd), representing the longest reported OS in previously treated HER2-positive metastatic breast cancer (mBC) to date.

Novel antireflux device shows potential for treatment of PPI-refractory GERD
Patients suffering from gastroesophageal reflux disease (GERD) and ineffective esophageal motility (IEM) may benefit from the novel RefluxStop device implantation, a safe and minimally invasive technology that offers potential benefits, a study has shown.

Kidney, heart benefits FLOW with semaglutide
Semaglutide reduces the risk of major kidney disease-related events and death from cardiovascular causes in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD), as shown in the FLOW* study presented at ERA 2024.

TMI, fludarabine, melphalan pass phase I trial as conditioning therapy in multiple myeloma
Fludarabine, melphalan, and total marrow irradiation (TMI) 900 cGy may be utilized as conditioning for allogeneic stem cell transplantation in patients with high-risk or relapsed/refractory multiple myeloma, as shown in a phase I trial.




